Hanmi Pharmaceutical Co. Ltd. has entered into an exclusive license agreement with Genentech Inc., a subsidiary of Roche, for the development and commercialization of Hanmi’s oral pan-RAF inhibitor HM95573 for solid tumors, in a major global deal worth up to $910m plus sales royalties to the South Korean firm.
Under the agreement, Genentech will obtain exclusive worldwide rights, excluding South Korea, to develop and commercialize HM95573. Hanmi will receive...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
